An antiretroviral injection administered every two months has been shown to be highly effective in preventing people from getting HIV in two large trials. Catherine Tomlinson asks what needs to happen before these injections become available to people in South Africa.
If South Africa is forced to go into a COVID-19 lockdown again, HIV support groups and adherence clubs should remain functional to make sure that everyone is supported, has regular access to information and treatment, and that people are motivated to adhere to treatment, argue Annah Maluleke and Solanga Milambo.
HIV medicines for children often taste bitter, pills are large, and for many children there is a lot of medication to take. This makes it hard to take treatment as prescribed. Tiyese Jeranji looks at the challenges with currently available HIV medicines for children, what innovations are in the pipeline, and how HIV treatment is being tailored to suit the needs of children.
Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.
A new antiretroviral medicine called dolutegravir is about to be introduced in the public healthcare system. Dr Tom Boyles outlines seven things people may want to consider before switching to the new drug.